David Berman, PhD, MD

Bio:

Dr. Berman is Head of Research and Development at Immunocore. Over his career, he has worked on multiple immune-oncology (IO) programs at all stages of development, including leadership roles in developing four approved biologics. Before arriving at Immunocore, David served as SVP and Head of AstraZeneca’s IO franchise, responsible for strategy and execution of the company’s late-stage IO program. Prior to that, he was head of the early-stage oncology program at MedImmune. David has also held senior development roles at Bristol-Myers Squibb, including as head of the IO exploratory development team and as Global Clinical Lead for the first approved IO checkpoint inhibitor and one of the first monoclonal antibodies approved for melanoma. Beginning in academia and throughout his career, David has led efforts to understand the mechanism of action of IO therapies and predict their benefits. David received his MD and PhD from the University of Texas Southwestern Medical School. He trained in pathology at the National Cancer Institute, followed by a fellowship at The John Hoppkins Hospital.